# A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients.

> **NCT04231682** · PHASE2 · WITHDRAWN · sponsor: **Albert Einstein Healthcare Network**

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Denosumab Injection
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04231682
- **Lead sponsor:** Albert Einstein Healthcare Network
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07-01
- **Primary completion:** 2024-01-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Grant support was withdrawn from Amgen Pharmaceuticals
- **Last updated:** 2020-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04231682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04231682, "A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04231682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*